42 results about "Pancreatic tissue" patented technology

The invention discloses an application of astaxanthin in preparation of a regulator for improving the gentisic acid level. On the basis of non-targeted metabonomics analysis, it is found for the first time that in the SAP pathogenesis process, the level of a flora metabolite, namely gentisic acid (GA), in intestinal contents is remarkably reduced, and in-vivo gentisic acid level can be remarkably callback through astaxanthin intervention. Further research proves that exogenous supplement of gentisic acid can effectively simulate the protection effect of astaxanthin, including improvement of pancreatic tissue pathological damage, reduction of serum lipase and amylase activity, and inhibition of systemic inflammatory response (down-regulation of IL-1beta, IL-6 and TNF-alpha and up-regulation of IL-10). The invention not only discloses a new mechanism that astaxanthin plays a therapeutic role through an'intestinal flora-metabolite 'axis, but also determines that gentisic acid is used as a novel drug target for treating SAP, and constructs a new method for screening drugs for treating SAP according to the novel drug target.

The present application relates to a deoxyribonuclease mutant and its application in preparing PDRN. The amino acid sequence of the deoxyribonuclease mutant is shown as SEQ ID NO. 1, and the nucleotide sequence of the encoding gene is shown as SEQ ID NO. 2. The present application also provides the application of the deoxyribonuclease mutant and / or the encoding gene of the deoxyribonuclease mutant in preparing PDRN, and the specific application method. The present application is based on the deoxyribonuclease expressed by the DNASE1 gene of bovine pancreas tissue, and the amino acids at positions 69, 132 and 215 are selected for iterative saturation mutation. Compared with the wild-type enzyme, the enzyme activity of the deoxyribonuclease mutant A69H-S132R-Q215C is increased by 2.15 times, reaching 4.1x10 6 U / mL, and the DNA extraction rate of salmon PDRN prepared by using the mutant enzyme prepared by the present application is 15.2%, the DNA content is 99.1%, and the molecular weight is 1.05 million Daltons, which is significantly improved compared with the wild-type enzyme, and the PDRN in this molecular weight range has more significant biological activity.

The invention discloses a preparation rich in polygonatum sibiricum polypeptide and application of the preparation in diabetes mellitus. The composition is prepared from rhizoma polygonati polypeptide, semeglutide, astaxanthin, an active agent and a ferroptosis mixture. Pharmacodynamic experiments show that in a diabetic mouse model, fasting blood glucose can be remarkably reduced, the serum insulin level can be increased, renal function indexes can be improved, and expression of NLRP3 inflammation pathway related proteins (NLRP3, Caspase-1 and IL-1beta) in pancreatic tissue can be remarkably inhibited. By integrating multiple mechanisms of blood glucose reduction, oxidation resistance, inflammation resistance, ferroptosis resistance and the like, multi-target collaborative intervention is realized, the pharmaceutical composition is remarkably superior to a single component in the aspects of blood glucose reduction, pancreas islet function protection and complication alleviation, and a new clinical strategy is provided for treatment of diabetes mellitus, especially type 1 diabetes mellitus.

The invention discloses a Ruditapes philippinarum miR-263b inhibitor and application thereof, and finds that Ruditapes philippinarum miR-263b can regulate and control innate immune response of a host by targeting RpSC2, negatively regulates activation of an immune-related signal channel in a vibrio infection process, and further, on the basis of a molecular regulation and control mechanism, the Ruditapes philippinarum miR-263b inhibitor can be used for inhibiting the infection of vibrio. The invention discloses a specific inhibitor which is completely complementary with a miR-263b mature body sequence. Experimental data show that after Ruditapes philippinarum is injected with the miR-263b inhibitor, the expression level of miR-263b in vivo is reduced, and the inhibition effect of miR-263b on RpSC2 is effectively relieved, so that the expression level of a target gene RpSC2 is up-regulated, an NF-kappa B immune signal channel is activated, the immune defense capability of the Ruditapes philippinarum on vibrio anguillarum is enhanced, the death rate after infection is remarkably reduced, and the Ruditapes philippinarum is prevented from being infected. The in-vivo bacterium loading amount is obviously reduced, and the pathological injury of hepatopancreas tissue is obviously relieved.

Systems and methods are provided for delivering a therapeutic treatment to a target population of cells (including, but not limited to, tumors, eyeballs, pancreatic tissue, liver tissue, and lung tissue) in a subject. The system includes an injectable aqueous solution in a vial enclosed with a septum. The solution comprises particles containing a therapeutic agent and having a coating surrounding the therapeutic agent, the coating comprising chitosan to provide controlled release of the agent from the particles. The solution also comprises a chitosan polymer in the form of a polymer gel matrix, further providing controlled release of the particles from the aqueous gel environment. There is also provided a method of making a freeze-dried powder placed in a vial containing a chitosan polymer and chitosan-coated particles, the powder when mixed with water forming the above injectable aqueous solution with particles and chitosan gel.

The invention provides an application of dimethyl fumarate in preparation of a medicine for treating hypertriglyceridemia type acute pancreatitis. Experiments prove that the dimethyl fumarate can treat the hypertriglyceridemia acute pancreatitis, and specifically, the dimethyl fumarate can relieve pancreatic tissue edema of the hypertriglyceridemia acute pancreatitis, relieve pancreatitis infiltration, relieve pancreatic acinus necrosis and the like. The invention provides a new strategy for treating hypertriglyceridemia acute pancreatitis, and has a good clinical application prospect.

The invention discloses a probiotic agent for relieving prediabetic action and application thereof, and belongs to the technical field of microorganisms. Experiments prove that bifidobacterium longum CCFM1113 and bifidobacterium adolescentis CCFM1386 composite probiotics can relieve the prediabetic stage, which is specifically embodied in reducing weight gain of mice in the prediabetic stage, regulating blood sugar metabolism, improving sugar tolerance and insulin resistance, protecting liver and pancreas tissues, being beneficial to increasing the diversity of intestinal flora, recovering the structure of the intestinal flora, and improving the immunity of the mice in the prediabetic stage. The invention also provides a preparation method of the bifidobacterium longum CCFM1113 and bifidobacterium adolescentis CCFM1386 composite probiotics. The bifidobacterium longum CCFM1113 and bifidobacterium adolescentis CCFM1386 composite probiotics. And the growth of beneficial bacteria related to metabolic disorder is enriched and regulated. The invention provides an important basis for developing a dietary formula suitable for prediabetic patients, and provides a new method for prevention and management of diabetes mellitus.

The invention relates to the technical field of novel application of compounds, in particular to novel application of meclozine and analogues thereof. The invention relates to an application of at least one of meclozine and analogues thereof or pharmaceutically acceptable salts or esters thereof in preparation of drugs for preventing and / or treating pancreatitis. The meclozine and the analogue thereof can obviously improve pancreatic tissue necrosis, inflammatory response and oxidative stress of pancreatitis, inhibit alveolar cell death and improve lung injury caused by pancreatitis, so that the meclozine and the analogue thereof can be used as a medicine for treating pancreatitis.

The invention discloses highly acetylated glucomannan and application thereof in preparation of a product with an effect of relieving prediabetes mellitus, and belongs to the technical field of medicines. In-vivo experiments prove that the glucomannan with high acetylation degree has the effect of relieving the prediabetic stage, which is specifically reflected in weight gain of mice in the prediabetic stage, regulation of blood glucose metabolism, improvement of glucose tolerance and insulin resistance, regulation of blood lipid metabolism, protection of liver and pancreatic tissues and reduction of epididymal fat cell size. The invention provides an important basis for developing a dietary formula suitable for prediabetic patients, and provides a new method for prevention and management of diabetes mellitus.

To provide various compositions and methods useful for the treatment of pancreatic cancer, such as pancreatic ductal adenocarcinoma (PDAC), and methods for activating pancreatic tissue-specific anti-tumor T cell immunity.SOLUTION: In certain embodiments, such methods comprise administration of IL33. In certain embodiments, such methods comprise administration of PD-1 and / or PD - L1 inhibitors.SELECTED DRAWING: None

This invention belongs to the field of biomedical technology and discloses the application of NP in the preparation of a glycemic regulator for aging type 2 diabetes. The NP is a nanoscale complex formed by hydrogen bonding of turtle egg peptide with a molecular weight less than 3 kDa and naringenin at a mass ratio of 100:1. The formulation promotes liver glycogen synthesis and repairs pancreatic tissue structure and pancreatic β-cell function by activating the hepatic IRS1 / PI3K / AKT / GSK-3β signaling pathway and upregulating GLUT2 protein expression. The NP provided by this invention can significantly reduce fasting blood glucose levels in aging type 2 diabetic mice, improve oral glucose tolerance, and reduce the area under the blood glucose curve. Simultaneously, by restoring insulin signal transduction, it significantly reduces the insulin resistance index and improves the insulin sensitivity index, with an improvement level approaching that of the classic hypoglycemic drug metformin.

The invention belongs to the field of pancreatic duct adenocarcinoma prediction, and provides a pancreatic duct adenocarcinoma prediction method and system based on oral flora. The pancreatic ductal adenocarcinoma prediction method based on oral flora comprises the following steps: acquiring relative abundance information of each biomarker in a potential biomarker set for diagnosing pancreatic ductal adenocarcinoma of a to-be-detected person; using the relative abundance information of each biomarker in the biomarker set and a pre-trained multivariate statistical model to obtain a probability value of suffering from pancreatic ductal adenocarcinoma; the method comprises the following steps: performing microbiome difference analysis on saliva, duodenal juice and pancreatic tissue samples of a pancreatic ductal adenocarcinoma patient group and a pancreatic benign disease patient group, and taking an intersection of differential bacteria in the samples to obtain a potential biomarker set for diagnosing the pancreatic ductal adenocarcinoma.

The invention discloses application of pancreatic protein peptide in preparation of products for improving insulin resistance and repairing pancreatic functions, and relates to the technical field of biological medicines. The pancreatic-derived protein peptide is extracted and purified from porcine pancreatic tissue through a specific enzymolysis process, the molecular weight is concentrated at 800-2000Da, and the pancreatic-derived protein peptide contains 12 essential amino acids. Experiments prove that the protein peptide can significantly improve insulin sensitivity and promote pancreatic beta cell proliferation through oral administration or intraperitoneal injection, and has no obvious toxic or side effect. The invention provides a novel treatment means for diseases related to type 2 diabetes and pancreatic function impairment, and has a wide clinical application prospect.

Disclosed herein are hepato-biliary-pancreatic organoid (“HBPO” or “HBP organoid”) compositions, and methods of making and using hepato-biliary-pancreatic organoid compositions. The disclosed compositions may have two or more functions selected from hepatic tissue function, biliary tissue function, exocrine pancreatic function, and endocrine pancreatic tissue function. Methods of treating individuals using the hepato-biliary-pancreatic organoid compositions is also disclosed.

To provide systems and methods for delivering a therapeutic treatment to a targeted population of cells of a subject.SOLUTION: The system includes an injectable aqueous solution in a vial enclosed with a septum. The injectable aqueous solution is formulated for injection into a targeted cell population. The solution includes particles containing a therapeutic agent and having a coating around the therapeutic agent, the coating including chitosan so as to provide controlled release of the agent from the particles. The solution further includes chitosan polymer in a form of a polymer gel matrix, further providing controlled release of the particles from the aqueous gel environment. Also provided are methods of manufacturing a lyophilized powder disposed within a vial containing chitosan polymer and chitosan coated particles, the powder forming the above-described injectable aqueous solution of particles and chitosan gel upon mixing with water. Also provided are methods of injecting the above-described injectable aqueous solution into a targeted population of cells, including but not limited to tumors, eyeballs, pancreatic tissue, liver tissue, and lung tissue, in order to provide localized delivery of a therapeutic agent.SELECTED DRAWING: Figure 12

The invention discloses an application of sgRNA targeting PGAM5 in acute pancreatitis as well as a product and a gene therapy drug of the sgRNA. In-vivo experiments prove that the PGAM5-targeted sgRNA can significantly inhibit PGAM5 gene expression, reduce pancreatic tissue inflammatory cell infiltration and reduce serum lipase and amylase levels, thereby blocking generation and development of AP. According to the invention, the targeted knockout of the PGAM5 gene by using the CRISPR-Cas9 system is proposed for the first time, and a new strategy is provided for the gene therapy of AP.

The present disclosure relates to a medical tissue adhesive for pancreatic plugging and the preparation method and use thereof. The medical tissue adhesive composition forming the medical tissue adhesive of the present disclosure comprises a medical tissue adhesive component and a chelating agent component; wherein the medical tissue adhesive component comprises a first component and a second component, the first component comprises four-arm polyethylene glycol amine, and the second component comprises four-arm-polyethylene glycol-succinimidyl glutarate; wherein m and n are natural numbers; and the chelating agent component comprises polyphenol. The medical tissue adhesive prepared from the medical tissue adhesive composition of the present disclosure is capable of firmly binding to the surface of the pancreatic tissue, and is capable of withstanding the dynamic pressure as a result of pancreatic juice leakage and the enzymatic degradation activity of pancreatic juice. More importantly, the medical tissue adhesive of the present disclosure has an excellent antibacterial ability and is capable of preventing the infection caused by the long-term accumulation of the leaked pancreatic juice.

The invention relates to application of indole-3-lactic acid in preparation of an acute pancreatitis resisting medicine, and belongs to the technical field of medicines. The invention provides an application of indole-3-lactic acid in preparation of an acute pancreatitis resisting medicine. An antibiotic mixture is used for conducting intragastric administration on a mouse, intestinal bacteria are removed, ILA and STS are subjected to intragastric administration on the mouse, leptofrog and arginine are injected into the abdominal cavity of the mouse for acute pancreatitis modeling, the acute pancreatitis resisting effect of ILA is studied, and the result shows that the amylase concentration in serum of the mouse subjected to intragastric administration of ILA is remarkably reduced; compared with STS, the ILA has the advantages that pancreatic tissue alveolar cell damage and inflammatory infiltration are obviously reduced, inflammatory cytokines in pancreatic tissue and serum are obviously reduced, and compared with STS, the ILA has a better protection effect, so that the ILA has the effect of resisting acute pancreatitis, and a new treatment way is provided for preventing and treating acute pancreatitis.

The invention discloses an efficient universal mouse pancreatic tissue single-cell suspension preparation method, and belongs to the technical field of cell biology. Pancreas are rich in digestive enzymes, so that the treatment difficulty of in-vitro cells is high, and a high-quality single-cell suspension is difficult to prepare by a traditional method. The method comprises the steps of reagent preparation, tissue sampling, tissue dissociation, red cracking and cleaning, AOPI dyeing quality inspection and the like. Components and concentrations of a tissue enzymatic hydrolysate, a cell cleaning solution and a cell suspension are determined in reagent preparation; the acquisition method of the pancreatic tissue of the mouse is defined by tissue sampling; the tissue dissociation adopts a two-round digestion mode, and the cut tissue is subjected to enzymolysis by using a compound enzyme solution under specific conditions; the cell precipitates are treated through red cracking and cleaning; aOPI dyeing quality inspection is used for analyzing cell count and motility rate. According to the method, the culture medium containing specific components and the compound enzyme liquid are creatively used, the problem that pancreas single cells are difficult to dissociate can be effectively solved, the single-cell suspension with high motility rate, high purity and low adhesion is obtained, and the requirements of downstream single-cell experiments are met.

The invention relates to the technical field of medical image processing, in particular to a pancreas focus tissue segmentation method and system based on multi-target recognition, and the method comprises the following steps: obtaining a pancreas tissue CT image; extracting a foreground region from the pancreatic tissue CT image, and performing classification identification on the foreground region through a pre-established classification model to obtain an attribute category of the foreground region; and according to the U-Net network corresponding to the attribute category of the foreground region, performing target segmentation on the foreground region to obtain a multi-target segmentation result of the pancreatic tissue. According to the method, through extraction and classification identification of the foreground regions, the corresponding intra-tumor tissue and peritumor tissue segmentation process is carried out on the foreground regions of the corresponding categories, interference of other regions is avoided, and the segmentation efficiency and segmentation precision of the intra-tumor region and the peritumor region are improved.

The invention provides application of a lucid ganoderma extract tablet in a product for treating type 2 diabetes mellitus, and the lucid ganoderma extract tablet can obviously increase the weight of a mouse, obviously reduce the increase of blood glucose of a T2DM mouse, effectively relieve impaired glucose tolerance of the T2DM mouse, effectively relieve dyslipidemia of the T2DM mouse and relieve the insulin resistance state of the T2DM mouse. Pancreatic tissue damage can be remarkably improved, and the effect of a dose group in the ganoderma lucidum extract tablet is most remarkable, so that the ganoderma lucidum extract tablet has the effect of treating type 2 diabetes mellitus.

The application discloses a duck hepatitis virus 1 type DHAV-1 / HNSQ and application thereof, and belongs to the field of animal virology and genetic engineering. The duck hepatitis virus 1 type DHAV-1 / HNSQ has been preserved in the China Center for Type Culture Collection on March 5, 2026, and the preservation number is CCTCC NO:V202622. The VP1 gene of the variant strain has a deletion of three consecutive nucleotides. Animal experiments show that, after the variant strain infects ducklings, in addition to causing typical duck viral hepatitis lesions, the variant strain can also stably cause a new phenotype, such as thinning of the heart wall, reduction of myocardial toughness and liquefaction necrosis of pancreatic tissue, which has never been reported in the prior art, thereby providing important biological materials for effective prevention and control of duck hepatitis and pathogenic mechanism research.

Use of muparfostat for the manufacture of a medicament for the treatment of non-functional pancreatic neuroendocrine tumors or exocrine pancreatic cancer. A pharmaceutical composition comprising muparfostat for the treatment of non-functional pancreatic neuroendocrine tumors or exocrine pancreatic cancer, said pharmaceutical composition further comprising one or more other anti-tumor drugs, such as chemotherapeutic drugs. The above medicament or pharmaceutical composition is capable of reducing the fibrosis of the pancreatic tissue in a patient with pancreatic cancer, effectively treating the pancreatic cancer.

The present invention relates in part to hybrid hydrogel scaffolds including a decellularized extracellular matrix (dECM) tissue, and a synthetic polymer. The dECM may include any suitable tissue including for example, lung tissue, heart tissue, heart-lung block tissue, skin tissue, liver tissue, pancreatic tissue, kidney tissue, and the like.

This invention belongs to the field of veterinary pharmacy and relates to the application of chenodeoxycholic acid (CDCA) in the preparation of drugs for treating canine acute pancreatitis. This invention is the first to propose the application of CDCA in the preparation of drugs for treating canine acute pancreatitis, clarifying that it achieves therapeutic effects by reducing pancreatic CT values, alleviating pancreatic edema and necrosis, and improving pancreatic tissue pathological damage, providing a novel strategy and drug option for targeted treatment of canine acute pancreatitis.

This invention proposes a method for preparing a single-cell suspension of porcine pancreatic cells and its application. The method includes the following steps: S1, taking porcine pancreatic tissue, removing surface fat, and mincing the tissue; S2, washing the tissue fragments, and then placing the tissue into a mixed enzyme dissociation solution for the first digestion; S3, after the first digestion, collecting the supernatant, and adding the remaining tissue to the mixed enzyme dissociation solution for a second digestion; S4, after the second digestion, collecting the supernatant and combining it with the supernatant from step S3, and filtering; S5, centrifuging the filtered dissociation solution, discarding the supernatant, and resuspending the cell pellet to obtain a cell suspension; the mixed enzyme dissociation solution includes trypsin, collagenase I, elastase, lipase, DNase I, heparin, sodium sulfate, and DH Kans buffer. The enzyme mixture of this invention has the effects of removing intercellular matrix, reducing cell aggregation, protecting cell membrane morphology, and reducing cell damage.

The invention discloses a pharmaceutical composition containing toosendanin compounds and application of the pharmaceutical composition, and relates to the technical field of medicines. The invention discloses application of toosendanin compounds or pharmaceutically acceptable salts or esters thereof in preparation of medicines for preventing and / or treating pancreatitis. The toosendanin compound can obviously improve pancreatic tissue necrosis, inflammatory response and oxidative stress of pancreatitis and improve lung injury caused by pancreatitis, and then can be used as a medicine for treating pancreatitis. The pharmaceutical composition provided by the invention has the advantages of definite curative effect, high safety, simple preparation process and the like, and provides a new drug choice for clinical prevention and treatment of pancreatitis.

The present invention relates to methods and compositions for regulating the migration and activity of type 2 innate lymphoid cells (ILC2) in order to modulate pancreatic glucagon secretion. The activation of sympathetic neuronal pathways innervating the intestine induces a reduction of ILC2 in the small intestine and promotes their rapid accumulation in pancreatic tissue. In the pancreas, the ILC2 secrete IL-5 and IL-13, which act directly on pancreatic α-cells expressing IL-5Rα and IL-13Rα to increase glucagon secretion.

This invention relates to an alanine-modified fullerene, its preparation method, pharmaceutical composition, and applications, belonging to the field of biomedical technology. It addresses the problems in existing treatments for type 1 diabetes, namely, the difficulty in safely and effectively protecting pancreatic β-cells while blocking autoimmune attacks, and the lack of pancreatic tissue-specific targeting ability in existing fullerene derivatives. The alanine-modified fullerene has the general formula shown in Formula I: C 70 - (Ala) n Equation I, where C 70 For fullerenes, Ala is an alanine group, and n is the number of atoms linked to each fullerene C. 70 The average number of alanine groups is taken as an integer from 1 to 20. The alanine-modified fullerene of the present invention has the targeting ability to specifically accumulate in pancreatic islet tissue in vivo, as well as the immunomodulatory function of inhibiting dendritic cell antigen presentation and regulating T cell differentiation, which can achieve efficient intervention on the core pathological links of type 1 diabetes.